Akeso (09926) rose nearly 3% in the morning, up 2.26% to HKD 42.95, with a turnover of HKD 72.7033 million at the time of publication.
According to the Intelligence Finance App, Akeso (09926) rose nearly 3% in the morning, up 2.26% to HKD 42.95, with a turnover of HKD 72.7033 million at the time of publication.
Minsheng Securities released research report stating that Akeso maintains its 'recommended' rating. The company's domestic sales and overseas authorization continue to be realized and the first profits are expected to be achieved in 2023, with sustained profits expected to be achieved from 2025 onwards.
The bank pointed out that on July 29, Akeso announced that the new drug application for the global first-line treatment of PD-1/VEGF dual antibody Yivoy single-agent for locally advanced or metastatic NSCLC with positive PD-L1 expression (PD-L1TPS≥1%) independently developed by the company has been accepted by China's National Medical Products Administration. Yivoy became the only drug in the world to demonstrate significantly better efficacy than pembrolizumab in head-to-head Phase III clinical trials as a single agent, providing significant positive results and demonstrating the clinical value of Yivoy globally. The huge potential of Yivoy in first-line NSCLC treatment is highly bullish. At the same time, the indications continue to expand, and it is believed that Yivoy will become a heavyweight drug in the world.